177 LUCC49 处于 III 期卵巢癌-猫眼课题宝

177 LUCC49 处于 III 期卵巢癌

批准号：

3738997

负责人：

EDWARD E PARTRIDGE

金额：

$0.0万

依托单位：

UNIVERSITY OF ALABAMA AT BIRMINGHAM

依托单位国家：

美国

项目类别：

财政年份：

资助国家：

美国

项目状态：

未结题

起止时间：

至

来源：

https://reporter.nih.gov/project-details/3738997

关键词：

antitumor antibody dosage drug administration routes drug screening /evaluation drug tolerance human subject human therapy evaluation immunoconjugates monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer pharmacology neoplasm /cancer radionuclide therapy neoplasm /cancer relapse /recurrence ovary neoplasms pharmacokinetics radiotracer

项目摘要

项目成果

EDWARD E PARTRIDGE的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

The purpose of this protocol is to determine the maximum tolerated dose of radioactive 177Lutetium bound to the monoclonal antibody CC49 (177Lu-CC49) when administered into the peritoneal cavity in patients with persistent or recurrent ovarian cancer following first or second-line chemotherapy; to examine its plasma pharmacokinetics; to determine its ability to localize to tumor sites; and to characterize its antitumor effects.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文